



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Daniel Bur et al.)	Confirmation No.: 4476
)	
Serial No.:	10/573,516)	Group Art Unit: 1625
)	
Filed:	March 27, 2006)	Examiner: John Mabry
)	
Title:	NOVEL PYRIDINE DERIVATIVES)	Docket No.: AC-43-US
)	

REQUEST FOR RECONSIDERATION

Office of Petitions
Commissioner for Patents
P.O.Box 1450
Alexandria, VA 22313-1450

Dear Sir/Madam:


The issue fees for the above-referenced application were paid on May 21, 2010. The name and the residence of the Assignee were inadvertently omitted from Form PTOL-85. On May 26, 2010, Patentees submitted a request for a certificate of correction pursuant to 37 C.F.R. 1.323 to state the name and address of the assignee, Actelion Pharmaceuticals LTD., Gewerbestrasse 16, Allschwil, Switzerland CH-4123. The fee pursuant to 37 C.F.R. 1.20(a) in the amount of \$100 and the fee pursuant to 37 CFR 1.17(i) in the amount of \$130.00 were also submitted. The assignment was recorded as set forth in 37 C.F.R. 3.11 on March 27, 2006, before the issuance of the patent.

On March 4, 2011, Patentees received a decision, denying said request for the certificate of correction, noting that the request should be directed to the office of Petitions. Therefore, submitted herewith to the Office of Petition is a copy of the original request for the certificate of correction, along with the receipt for the \$230 fees paid on May 26, 2010. Reconsideration for a certificate of correction is therefore requested.

It is believed no other fees are required. If any other additional fees are presently required, the Commissioner is authorized to charge any additional fees, or credit any overpayment, to deposit account No. 50-4255.

Respectfully Submitted,

Date 3/29/2011

By 
Brittany La
Reg. No. 58,337

Hoxie & Associates LLC
75 Main Street, Suite 301
Millburn, NJ 07041
(973) 912-5232



Best Available Copy

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Daniel Bur *et al.*

Examiner: John Mabry

Patent No.: 10/573,516

Group Art Unit: 1625

Filed: March 27, 2006

Docket No: AC-43-US

Title: NOVEL PYRIDINE DERIVATIVES)

REQUEST FOR A CERTIFICATE OF CORRECTION

Commissioner for Patents
P.O.Box 1450
Alexandria, VA 22313-1450

Dear Sir/Madam:

The Issue Fee for the above-referenced application was filed on May 21, 2010. The name of the Assignee and the Residence of the Assignee were inadvertently omitted. Applicants hereby request for a Certificate of Correction pursuant to 37 C.F.R. 1.323 to state the name and address of the assignee, Actelion Pharmaceuticals LTD., Gewerbestrasse 16, Allschwil, Switzerland Ch-4123. An assignment was submitted for the recordation as set forth in 37 C.F.R. 1.20(a) in the amount of \$100 and the fee pursuant to 37 C.F.R. in the amount of \$130.00 in accordance with instructions concurrently submitted.

If any other additional fees are presently required, the Commissioner is authorized to charge any additional fees, if needed, or credit any overpayment, to deposit account No. 50-4255. If there are any questions, especially ones relating to payments, please contact the undersigned, or if the undersigned is not available, please contact Brian W. Stegman at the same number.

Respectfully Submitted,

Date May 26, 2010

By Brian W. Stegman
Brian W. Stegman
Reg. No. 30,977
Hoxie & Associates LLC
75 Main Street, Suite 301
Millburn, NJ 07041
(973) 912-5232



Best Available Copy

Electronic Acknowledgement Receipt

EFS ID:	7689587
Application Number:	10573516
International Application Number:	
Confirmation Number:	4476
Title of Invention:	<div>DOCKETED \$0.4 Hoxie & Assoc. 5/26/10</div> PYRIDINE DERIVATIVES
First Named Inventor/Applicant Name:	Daniel Bur
Customer Number:	50446
Filer:	Thomas Hoxie/Stephanie Owusu-Hemeng
Filer Authorized By:	Thomas Hoxie
Attorney Docket Number:	AC-43-US
Receipt Date:	26-MAY-2010
Filing Date:	27-MAR-2006
Time Stamp:	12:00:46
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes				
Payment Type	Credit Card				
Payment was successfully received in RAM	\$230				
RAM confirmation Number	7786				
Deposit Account					
Authorized User					
File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)

Best Available Copy

1	Request for Certificate of Correction	AC_43_US_REQ.pdf	164200 c6fc0ba6ba73b7053611a610196d5010c51a2c2f	no	1
Warnings:					
Information:					
2	Fee Worksheet (PTO-875)	fee-info.pdf	32138 76d5eb660ff4f8be425d68f64c10bd0544eb9fd7	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			196338		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					

Acknowledgement Receipt

The USPTO has received your submission at **12:00:46** Eastern Time on **26-MAY-2010**.

\$ **230** fee paid by e-Filer via *RAM* with Confirmation Number: 7786.

eFiled Application Information

EFS ID	7689587
Application Number	10573516
Confirmation Number	4476
Title	PYRIDINE DERIVATIVES
First Named Inventor	Daniel Bur
Customer Number or Correspondence Address	50446
Filed By	Thomas Hoxie/Stephanie Owusu-Hemeng
Attorney Docket Number	AC-43-US
Filing Date	27-MAR-2006
Receipt Date	26-MAY-2010
Application Type	U.S. National Stage under 35 USC 371



DOCKETED SOH
Hoxie & Assoc. 5/26/10

Application Details

Submitted Files	Page Count	Document Description	File Size	Warnings
AC_43_US_REQ.pdf	1	Request for Certificate of Correction	164200 bytes	◇ PASS
fee-info.pdf	2	Fee Worksheet (PTO-875)	32138 bytes	◇ PASS

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this

Acknowledgement Receipt will establish the international filing date of the application.

If you need help:

- *Call the Patent Electronic Business Center at (866) 217-9197 (toll free) or e-mail EBC@uspto.gov for specific questions about Patent e-Filing.*
- *Send general questions about USPTO programs to the [USPTO Contact Center \(UCC\)](#).*
- *If you experience technical difficulties or problems with this application, please report them via e-mail to [Electronic Business Support](#) or call 1 800-786-9199.*

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

Page 1 of 1

PATENT NO. : 7,750,161

APPLICATION NO.: 10/573,516

ISSUE DATE : July 6, 2010

INVENTOR(S) : Bur et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the first page of the issued patent, left hand column, below the list of inventors should read: "Assignee: Actelion Pharmaceuticals LTD., Gewerbestrasse 16, Allschwil, Switzerland Ch-4123"

MAILING ADDRESS OF SENDER (Please do not use customer number below):
Hoxie & Associates LLC 75 Main St, Suite 301 Millburn, NJ 07041

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.